Details for Patent: 7,745,409

Title:	Methods and compositions for the treatment of gastrointestinal disorders
Abstract:	The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s):	Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA)
Assignee:	Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Filing Date:	Dec 03, 2007
Application Number:	11/949,340
Claims:	1. A polypeptide comprising the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:125) or a pharmaceutically acceptable salt thereof. 2. The polypeptide of claim 1 consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:125) or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising the polypeptide of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 4. The polypeptide of claim 1 or a pharmaceutically acceptable salt thereof, wherein the polypeptide activates the guanylate cyclase C receptor. 5. A pharmaceutical composition comprising the polypeptide of claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 6. The polypeptide of claim 1 consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:125). 7. A pharmaceutical composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier or excipient.